Sanfilippo Syndrome Market Report 2026

Sanfilippo Syndrome Market Overview

• Sanfilippo Syndrome market size has reached to $9.21 billion in 2025 • Expected to grow to $15.02 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Rise In Gene Therapies Driving The Growth Of The Market Due To Their Potential To Treat Genetic Disorders • Market Trend: Advancements In Gene Therapy Show Promise For Treating Rare Genetic Disorders • North America was the largest region in 2025.

What Is Covered Under Sanfilippo Syndrome Market?

Sanfilippo syndrome, also known as mucopolysaccharidosis type III (MPS III), is a rare genetic disorder caused by enzyme deficiencies that impair the body’s ability to break down heparan sulfate, a complex sugar. This leads to the accumulation of toxic substances in cells, primarily affecting the central nervous system. The disease is characterized by progressive neurodegeneration, developmental delays, behavioral issues, and a decline in motor and cognitive functions. The main treatment of sanfilippo syndrome includes enzyme replacement therapy (ERT), gene therapy, genistein, and other treatments. Enzyme replacement therapy (ERT) supplements deficient or faulty enzymes to reduce the buildup of harmful substances in individuals with sanfilippo syndrome. Various diagnostic methods used include glycosaminoglycan (GAG) analysis, genomic DNA sequencing, activity assays, and others, and are utilized by various end users, such as hospitals and research institutions.

What Is The Sanfilippo Syndrome Market Growth Forecast?

The sanfilippo syndrome market size is expected to see rapid growth in the next few years. It will grow to $15.02 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advancement of aav-based gene therapies, increasing orphan drug designations and incentives, rising healthcare expenditure on rare diseases, expanding newborn screening initiatives, growing investment from biotech and pharmaceutical companies. Major trends in the forecast period include increasing clinical trial activity for sanfilippo syndrome therapies, growing adoption of gene therapy approaches in pediatric neurodegenerative disorders, rising use of advanced diagnostic techniques for early detection, expanding compassionate use and early access programs for rare diseases, higher collaboration between biotech firms and research institutions.

Global Sanfilippo Syndrome Market Segmentation

1) By Treatment: Enzyme Replacement Therapy, Gene Therapy, Genistein, Other Treatments 2) By Diagnosis: Glycosaminoglycan Analysis (GAG Analysis), Genomic Deoxyribonucleic Acid Sequencing (Genomic DNA Sequencing), Activity Assay, Other Diagnosis 3) By End-User: Hospitals, Research Institutions Subsegments: 1) By Enzyme Replacement Therapy: Intravenous Enzyme Replacement Therapy, Intrathecal Enzyme Replacement Therapy, Intracerebroventricular (ICV) Enzyme Replacement Therapy 2) By Gene Therapy: Adeno-Associated Virus (AAV)-Based In Vivo Gene Therapy, Lentiviral Vector–Based Ex Vivo Gene Therapy, Non-Viral Vector Gene Delivery 3) By Genistein: Oral Genistein Supplementation, High-Dose Genistein Regimens, Low-Dose Genistein Regimens 4) By Other Treatments: Substrate Reduction Therapy (SRT), Stem Cell Therapy, Anti-Inflammatory Agents, Symptomatic Management Drugs

What Is The Driver Of The Sanfilippo Syndrome Market?

The increasing focus on gene therapies is expected to propel the growth of the sanfilippo syndrome market going forward. Gene therapies refer to medical treatments that modify or replace faulty genes to treat or prevent diseases. The increasing focus on gene therapies is due to their potential to treat genetic disorders, rare diseases, and chronic conditions by targeting the root cause at the molecular level. Gene therapies help treat Sanfilippo syndrome by delivering functional copies of the defective gene to restore enzyme production, reducing the accumulation of harmful substances in cells. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, reported that in Q4 2023, the number of phase III gene therapy clinical trials rose by 10%, marking the first quarterly increase since Q3 2022. Therefore, the increasing focus on gene therapies is driving the growth of the sanfilippo syndrome industry.

Key Players In The Global Sanfilippo Syndrome Market

Major companies operating in the sanfilippo syndrome market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co Ltd, Denali Therapeutics Inc, REGENXBIO Inc, Greenwood Genetic Center, ArmaGen Inc, Abeona Therapeutics Inc, Orchard Therapeutics plc, Allievex Corporation, Lysogene SA, Sio Gene Therapies Inc, Abeona Therapeutics Europe, Spark Therapeutics Inc, PTC Therapeutics Inc, Neurogene Inc, Taysha Gene Therapies Inc, MeiraGTx Holdings plc, Sangamo Therapeutics Inc, Freeline Therapeutics Holdings plc, LogicBio Therapeutics Inc

Global Sanfilippo Syndrome Market Trends and Insights

Major companies operating in the sanfilippo syndrome market are focusing on developing innovative treatments, such as gene therapies, to improve patient outcomes and slow disease progression. Gene therapy is a medical approach that uses genes to prevent, treat, or cure diseases by correcting or replacing faulty genes in the body. For instance, in February 2025, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, announced new findings on UX111 (ABO-102), an AAV gene therapy for sanfilippo syndrome Type A (MPS IIIA). The treatment demonstrated statistically significant improvements in Bayley-III raw scores for cognition, receptive communication, and expressive communication. Furthermore, it led to a substantial and sustained reduction in cerebrospinal fluid (CSF) heparan sulfate (HS) levels, which correlated with improved clinical outcomes.

What Are Latest Mergers And Acquisitions In The Sanfilippo Syndrome Market?

In April 2025, Spruce Biosciences, a US-based biopharmaceutical company, acquired tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) from BioMarin Pharmaceutical Inc. for an undisclosed amount. With this acquisition, Spruce aims to strengthen its rare-disease pipeline and focus its corporate strategy on a near-term commercial opportunity in MPS IIIB, bridging significant unmet need with a development-ready asset. BioMarin Pharmaceutical Inc. is a US-based biotechnology company that develops therapies for serious genetic and rare diseases, including enzyme replacement therapies for lysosomal storage disorders.

Regional Outlook

North America was the largest region in the sanfilippo syndrome market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sanfilippo Syndrome Market?

The sanfilippo syndrome market consists of revenues earned by entities by providing services such as substrate reduction therapies (SRT), and other emerging treatment modalities and related diagnostic services, supportive care solutions, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The sanfilippo syndrome market also includes sales of antiepileptic drugs, sleep aids, and behavioral management medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sanfilippo Syndrome Market Report 2026?

The sanfilippo syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sanfilippo syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.